Lonsurf (trifluridine and tipiracil) tablets

Lonsurf is an oral chemotherapy medication composed of two active ingredients: trifluridine and tipiracil. It was developed by Taiho Pharmaceutical Co., Ltd., a subsidiary of Otsuka Holdings Co., Ltd. Based on its clinical profile, it is primarily used for the treatment of patients with metastatic colorectal cancer and metastatic gastric or gastroesophageal junction adenocarcinoma who have previously failed other treatments.

The drug's manufacturing centers around Taiho Pharmaceutical's facilities in Japan. In the United States, it is marketed and distributed through Taiho Oncology, Inc., while in Europe and other international markets, it is often commercialized through partnerships with companies like Servier. The brand remains under the ultimate global ownership of Otsuka Holdings, a leading Japanese healthcare corporation.